Aldevron

09/10/2026

For most people, waking up without pain feels ordinary. For Victoria Gray, it felt impossible.

After decades of living with sickle cell disease, she woke up one morning and realized the pain was gone. The feeling was so unfamiliar that she thought she had died.

During National Sickle Cell Awareness Month, we recognize the patients, families, advocates, clinicians, researchers, and teams working toward more treatment options and more hope.

09/09/2026

How do you keep pace with rapid innovation in RNA therapeutics?

The answer increasingly depends on the analytical tools used to characterize, monitor, and optimize RNA products throughout development.

Explore key challenges, emerging approaches, and opportunities shaping the future of RNA analytics in this presentation from Aldevron: https://ald.bio/46ewgXW

As RNA therapeutics advance, modern analytics are evolving to support release, characterization, delivery evaluation, and stability monitoring.

09/09/2026

Before becoming the first person treated with a CRISPR-based gene editing therapy, Victoria Gray was a mother living with severe sickle cell disease.

When a teacher told her that her son feared she would die while he was at school, everything changed. That moment became her reason to keep fighting.

This month, we are sharing stories that remind us why progress matters.

09/08/2026

Every breakthrough begins with a question. Every answer starts with research.

On Stand Up To Cancer Day, we recognize the patients, families, clinicians, and scientists who continue driving progress against one of the world's greatest health challenges. Their determination fuels discoveries that bring hope to countless lives.

Today, and every day, we stand up for the future of cancer research.

09/08/2026

We're heading to the CAR-TCR Summit, September 15-17 in Boston, to join conversations on advancing scalable CAR-T and TCR therapies through innovation, collaboration, and manufacturing strategies designed for long-term success.

Whether you're focused on development, manufacturing, or commercialization, we'd love to discuss how to navigate the evolving cell therapy landscape.

Visit us at Booth #27 and check out Poster #126 in The Pavilion.

For more information: https://ald.bio/4yeDFlY

09/07/2026

Behind every achievement is a team of people who show up, solve problems, support one another, and keep moving forward.

This Labor Day, we're grateful for the dedication and expertise of our associates across Aldevron. Thank you for the work you do and the impact you make every day in support of our customers, our colleagues, and the patients who ultimately benefit from scientific innovation.

In observance of today, September 7th, our U.S. offices will be closed as we take time to recognize and celebrate the contributions of the workforce that drives progress forward. We will be back in the office tomorrow (Tuesday, September 8th).

Wishing everyone a safe, restful, and enjoyable Labor Day.

09/03/2026

We're looking forward to joining the RNA Vaccines & Therapeutics Conference in London, where leaders from across academia, biotech, and pharma will come together to explore the innovations shaping the future of RNA medicines. Discussions will span RNA design, delivery, manufacturing, scale-up, and the collaborative pathways needed to move promising therapies from concept to clinic.

Our very own Christian Boada will also be presenting his scientific poster: "mRNA Drug Substance Journey to LNP Drug Product: Scale-Up Via Microfluidic Mixing."

If you're attending, we'd love to connect and discuss how scalable manufacturing strategies can help advance the next generation of RNA vaccines and therapeutics.

09/02/2026

How confident are you in your viral vector CMC strategy?

Early CMC decisions can have a lasting impact on development timelines, manufacturing scalability, regulatory readiness, and long-term program flexibility.

That's why we've created a practical CMC Planning Checklist for Viral Vector Programs to help teams evaluate key considerations before timelines and processes become more fixed.

The checklist covers:
✅ Development strategy alignment with future clinical goals
✅ Plasmid design and quality considerations
✅ Manufacturing and scale readiness
✅ Regulatory and documentation expectations

Download the checklist and assess your program's readiness for the next stage of development: https://ald.bio/4dh45v5

09/01/2026

Lead optimization moves quickly. Your RNA supplier should too.

Whether you're screening multiple constructs, evaluating doses, or advancing promising candidates, Aldevron's online store makes it easy to order the research grade mRNA you need, when you need it.

Key benefits include:
• Instant pricing with no sales process
• Flexible quantities sized for your research stage
• Faster turnaround enabled by cell-free DNA template production
• Research grade material backed by extensive clinical manufacturing experience

And when your program progresses? You're already working with a manufacturer trusted to support RNA programs from discovery through commercialization.

Spend less time sourcing materials and more time generating data. Order now: https://ald.bio/4g89i9h

What would make ordering RNA materials easier for your team?

09/01/2026

During National Sickle Cell Awareness Month, we recognize the patients, families, caregivers, advocates, clinicians, and researchers working to advance understanding of sickle cell disease and improve the future of care.

Last year, Aldevron welcomed Victoria Gray, the first person to have their cells edited using CRISPR for sickle cell disease, as part of our Advance Beyond symposium. Her story was a powerful reminder that scientific progress is ultimately measured by its impact on people and families.

Victoria spoke about the realities of living with sickle cell disease, the hope that research can create, and the importance of continuing to expand access for patients who need it most.

This month, we honor the resilience of the sickle cell community and the individuals whose experiences continue to inspire the pursuit of new discoveries and new possibilities.